AC6 Stock Overview
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AlzeCure Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr0.16 |
| 52 Week High | kr0.52 |
| 52 Week Low | kr0.12 |
| Beta | 0.39 |
| 1 Month Change | -27.60% |
| 3 Month Change | -23.08% |
| 1 Year Change | -57.22% |
| 3 Year Change | -77.18% |
| 5 Year Change | -78.08% |
| Change since IPO | -80.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| AC6 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -2.0% |
| 1Y | -57.2% | -31.9% | -0.3% |
Return vs Industry: AC6 underperformed the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: AC6 underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| AC6 volatility | |
|---|---|
| AC6 Average Weekly Movement | 22.7% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AC6's share price has been volatile over the past 3 months.
Volatility Over Time: AC6's weekly volatility has increased from 16% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 11 | Martin Jönsson | www.alzecurepharma.se |
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline products include ACD856, which is in phase I clinical trial to treat Alzheimer’s disease, sleep disorders, traumatic brain injuries, and Parkinson’s disease; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain.
AlzeCure Pharma AB (publ) Fundamentals Summary
| AC6 fundamental statistics | |
|---|---|
| Market cap | €11.08m |
| Earnings (TTM) | -€3.20m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.5x
P/E RatioIs AC6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AC6 income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr37.17m |
| Earnings | -kr37.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 25, 2024
| Earnings per share (EPS) | -0.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AC6 perform over the long term?
See historical performance and comparison